- •We sought to determine parameter estimates made in cost-effectiveness analyses (CEAs) in prostate cancer and identified 508 model estimates.
- •We noted substantial heterogeneity in parameter estimates made across CEAs.
- •To assess the impact of this heterogeneity, we constructed a Markov cohort model using the parameters we identified from our systematic review, which demonstrated 3 separate acceptability determinations.
- •Such variation suggests that the parameter estimates underlying individual CEAs must be considered carefully before altering clinical management decisions or health policy.
Purchase one-time access:Academic and Personal
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Cancer statistics, 2020.CA Cancer J Clin. 2020; 70: 7-30
NCCN clinical practice guidelines in oncology: prostate cancer. 1.2020 version 2020. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed March 16, 2020.
- Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012.Cancer. 2020; 126: 717-724
- ∗Explorer: an interactive website for SEER cancer statistics. Surveillance Research Program, National Cancer Institute.https://seer.cancer.gov/explorer/Date accessed: March 1, 2021
- Radiation oncology APM: why us? Why now?.Int J Radiat Oncol Biol Phys. 2019; 105: 22-24
- A cost-effectiveness modelling study of strategies to reduce risk of infection following primary hip replacement based on a systematic review.Health Technol Assess. 2016; 20: 1-144
- Period life table, 2017. Social Security Administration.https://www.ssa.gov/oact/STATS/table4c6.htmlDate accessed: August 10, 2020
- Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold.N Engl J Med. 2014; 371: 796-797
- Consolidated health economic evaluation reporting standards (CHEERS) statement.Eur J Health Econ. 2013; 14: 367-372
- Proton therapy vs. IMRT for low or intermediate risk prostate cancer (PARTIQoL). ClinicalTrials.gov identifier: NCT01617161. ClinicalTrials.gov.https://clinicaltrials.gov/ct2/show/NCT01617161Date accessed: June 15, 2021
- A prospective comparative study of outcomes with proton and photon radiation in prostate cancer (COMPPARE). ClinicalTrials.gov Identifier: NCT03561220. ClinicalTrials.gov.https://clinicaltrials.gov/ct2/show/NCT03561220Date accessed: June 15, 2021
- Cost-effectiveness of intensity-modulated radiotherapy in prostate cancer.Clin Oncol (R Coll Radiol). 2012; 24: 521-531
- Cost-effectiveness analysis of SBRT versus IMRT for low-risk prostate cancer.Am J Clin Oncol. 2014; 37: 215-221